Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Transfus Med ; 27(1): 43-51, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27862486

ABSTRACT

OBJECTIVES: To investigate the specificities and level of HLA class I antibodies in selected cases referred for suspected foetal and neonatal alloimmune thrombocytopenia (FNAIT). BACKGROUND: FNAIT occurs in 1 : 1-2000 live births, whereas maternal immunisation against human leukocyte antigen (HLA) class I is common. Whether HLA class I antibodies alone can cause FNAIT is debatable. MATERIAL AND METHODS: A total of 260 patient samples were referred between 2007 and 2012. Referrals with maternal HLA class I antibodies and no other cause for the neonatal thrombocytopenia were included for analysis (cases, n = 23). HPA-1a negative mothers were excluded. Control groups were screened positive mothers of healthy neonates (controls, n = 33) and female blood donors (blood donors, n = 19). LABScreen single antigen HLA class I beads was used for antibody analysis. Clinical records were reviewed for cases. RESULTS: All groups had broad antibody reactivity. Cases had more antibodies with high SFI levels compared with the controls (SFI>9999; medians 26, 6 and 0; P < 0·05) and higher overall median HLA-ABC and HLA-B SFI (P < 0·05). Many of the antibodies were reactive with rare alleles. When reviewing the clinical records, several of the cases had other contributing factors to the thrombocytopenia. There was no correlation between foetal platelet count and antibody levels. CONCLUSION: Mothers of thrombocytopenic neonates had higher levels of HLA class I antibodies compared with control groups of women with healthy children and female blood donors. However, clinical outcome and antibody response correlated poorly in the heterogeneous case group, indicating a multifactorial cause to the thrombocytopenia in the majority of cases.


Subject(s)
Autoantibodies/blood , Fetomaternal Transfusion/blood , Histocompatibility Antigens Class I , Thrombocytopenia, Neonatal Alloimmune/blood , Female , Fetomaternal Transfusion/complications , Humans , Infant, Newborn , Male , Pregnancy , Thrombocytopenia, Neonatal Alloimmune/etiology
2.
Tissue Antigens ; 81(1): 35-43, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23216287

ABSTRACT

The human leukocyte antigen (HLA) antigen, allele and haplotype frequencies of the Finnish population are quite unique because of a rather restricted and homogeneous gene pool. This has a strong influence on finding suitable donors for transplant patients; hence knowledge about the HLA frequencies of the patient population is essential. Here we report the HLA antigen frequencies for a large population sample and show high resolution HLA allele frequencies for 11 loci, including the rarely typed DPA1 and DQA1 loci. Furthermore, the most common Finnish high resolution haplotypes are presented for five HLA loci. The study shows that there are fewer HLA haplotypes in the Finnish population compared with mixed populations, and the common Finnish HLA haplotypes are more frequent. Using HLA antibody identification and panel reactive antibody calculations we show that a virtual population-specific panel, combined with single antigen testing, gives a more accurate and reliable estimate of the reactivity of the recipient serum against potential solid organ donors within the Finnish population. The results can be directly used to improve donor search for patients waiting for stem cell transplantation and to allocate highly immunised patients accurately to acceptable mismatch programs.


Subject(s)
Alleles , Gene Frequency , HLA Antigens/genetics , Haplotypes , Finland , Humans , Tissue Donors , White People
3.
Vox Sang ; 98(3 Pt 1): e295-363, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20432515

ABSTRACT

A critical aspect of blood transfusion is the timely provision of high quality blood products. This task remains a significant challenge for many blood services and blood systems reflecting the difficulty of balancing the recruitment of sufficient donors, the optimal utilization of the donor's gift, the increasing safety related restrictions on blood donation, a growing menu of specialized blood products and an ever-growing imperative to increase the efficiency of blood product provision from a cost perspective. As our industry now faces questions about our standard practices including whether or not the age of blood has a negative impact on recipients, it is timely to take a look at our collective inventory management practices. This International Forum represents an effort to get a snap shot of inventory management practices around the world, and to understand the range of different products provided for patients. In addition to sharing current inventory management practices, this Forum is intended to foster an exchange of ideas around where we see our field moving with respect to various issues including specialty products, new technologies, and reducing recipient risk from blood transfusion products.


Subject(s)
Blood Banks/organization & administration , Inventories, Hospital/organization & administration , Adult , Americas , Asia , Blood Banks/statistics & numerical data , Blood Preservation/methods , Blood Preservation/standards , Blood Preservation/statistics & numerical data , Blood Transfusion/standards , Blood Transfusion/statistics & numerical data , Child , Cryopreservation , Erythrocyte Aging , Europe , Humans , Infant, Newborn , Medical Records , Surveys and Questionnaires , Time Factors
5.
Haemophilia ; 14(2): 233-41, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18081827

ABSTRACT

Arthropathy is prevalent in patients with haemophilia and inhibitors and is a major source of pain and disability, significantly reducing quality of life. Recombinant activated factor VII (rFVIIa; NovoSeven is one of the treatments available for acute life-threatening bleeding episodes in haemophilia patients with inhibitors. It has also been used successfully in a range of orthopaedic surgical procedures in these patients. This is a review of published data on elective orthopaedic procedures in haemophilia patients with inhibitors under cover of rFVIIa from January 2002 to November 2006. Articles were retrieved from MEDLINE using specified search parameters. Twelve articles covering a total of 80 orthopaedic procedures were identified. In the vast majority of cases, rFVIIa provided safe and effective haemostatic cover during orthopaedic surgery with no bleeding complications. There was variation in the administered dose, although the majority of patients were treated with 90 mug kg(-1) bolus followed by either continuous infusion or bolus infusion. Of those cases reporting bleeding complications, most were considered to be related to an inadequate amount of rFVIIa. The cumulative experience presented here suggests that rFVIIa is safe and effective for providing adequate haemostatic cover for haemophilia patients with inhibitors undergoing orthopaedic surgery. The optimal dosing regimen and mode of administration has yet to be identified. Further controlled trials are needed to confirm these experiences.


Subject(s)
Blood Coagulation Factor Inhibitors/blood , Factor VIIa/therapeutic use , Hemophilia A/drug therapy , Hemophilia A/surgery , Hemostatics/therapeutic use , Musculoskeletal Diseases/surgery , Hemophilia A/immunology , Hemostasis, Surgical , Humans , Musculoskeletal Diseases/drug therapy , Musculoskeletal Diseases/immunology , Orthopedic Procedures , Postoperative Hemorrhage/prevention & control , Recombinant Proteins/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...